Order Article Reprints

González-Ortiz A, Pulido-Capiz A, Castañeda-Sánchez CY, Ibarra-López E, Galindo-Hernández O, Calderón-Fernández MA, López-Cossio LY, Díaz-Molina R, Chimal-Vega B, Serafín-Higuera N, et al. eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model. Cells. 2022; 11(24):4069. https://doi.org/10.3390/cells11244069

González-Ortiz, Alina, Angel Pulido-Capiz, César Y. Castañeda-Sánchez, Esmeralda Ibarra-López, Octavio Galindo-Hernández, Maritza Anahí Calderón-Fernández, Leslie Y. López-Cossio, Raul Díaz-Molina, Brenda Chimal-Vega, Nicolás Serafín-Higuera, and et al. 2022. "eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model" Cells 11, no. 24: 4069. https://doi.org/10.3390/cells11244069

González-Ortiz, A., Pulido-Capiz, A., Castañeda-Sánchez, C. Y., Ibarra-López, E., Galindo-Hernández, O., Calderón-Fernández, M. A., López-Cossio, L. Y., Díaz-Molina, R., Chimal-Vega, B., Serafín-Higuera, N., Córdova-Guerrero, I., & García-González, V. (2022). eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model. Cells, 11(24), 4069. https://doi.org/10.3390/cells11244069